Prostate Specific or Enriched Genes as Composite Biomarkers for Prostate Cancer
Annual rept. 8 Jan 2007-7 Jan 2008
INSTITUTE FOR SYSTEMS BIOLOGY SEATTLE WA
Pagination or Media Count:
Purpose and scope of research To evaluate prostate specific genes such as WDR19, NDRG1, Transgelin 2 as diagnosis and prognosis markers for prostate cancers. Major findings 1 Serum Samples collections We have retrieved more than 200 prostate cancer, BPH and normal matched control serum samples from the University of Washington Urology serum bank. 2 WDR19 antibody production and ELISA assay development. We have generated Rabbit monoclonal antibodies against WDR19. We have obtained six hybridoma clones. We are in the process of matching these monoclonal antibodies against each other and against two mouse monoclonal antibodies that we have previously generated to develop a sensitive ELISA assay. 3. Novel biomarker Transgelin 2. We have identified a novel biomarker Transgelin 2, which is a prostate specific gene, as a marker that showed lower expression levels in prostate cancer patients compared to normal individuals by Western Blot analysis. We are generating antibodies against Transgelin 2 and will develop an ELISA assay for Transgelin 2. 4 WDR19 as a prognosis marker for prostate cancer. We showed that WDR19 expression in prostate cancer tissues by IHC is a good prognostic marker for prostate cancer.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research